Abstract
Carisoprodol (N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate), a congener of meprobramate, is recommended by its manufacturers as a centrally acting musculoskeletal relaxant with mild anticholinergic, antipyretic, and analgesic properties. Many authorities maintain that the beneficial effects of carisoprodol noted in the treatment of patients with muscle spasm of local origin are related more to modification of central pain perception than they are to muscle relaxant properties [1,2]. Drowsiness, vertigo, weakness, and lassitude have accompanied carisoprodol therapy, but these adverse effects occur infrequently in adults who are taking recommended dosages of 250 or 350 mg four times daily [3].
Issue Section:
Research Papers
References
1.
Goodman
, L. S.
and Gilman
, A.
, Eds., The Pharmacological Basis of Therapeutics
, 4th ed., Macmillan
, New York
, 1970
, pp. 229 and 176.2.
Modell
, W.
, Drugs of Choice 1972–1973
, The C. V. Mosby Co.
, St. Louis
, 1972
, p. 271.3.
New Drugs Evaluated by the A.M.A. Council on Drugs
, American Medical Association
, Chicago
, 1967
, pp. 154
–155
.4.
Goldberg
, D.
, “Carisoprodol Toxicity
,” Military Medicine
, Vol. 134
, 1969
, pp. 597
–601
.5.
Maes
, R.
, Bouche
, R.
, and Laruelle
, L.
, “Détermination Quantitative de Meprobamate et de Carisoprodol par Chromatographie en Phase Gazeuse, dans Différents Cas d'Intoxications
,” Journal Européan de Toxicologie
, Vol. 3
, 1970
, pp. 140
–143
.6.
Douglas
, J. F.
, Ludwig
, B. J.
, and Schlosser
, A.
, “The Metabolic Fate of Carisoprodol in the Dog
,” Journal of Pharmacology and Experimental Therapeutics
, Vol. 138
, 1962
, pp. 21
–27
.
This content is only available via PDF.
All rights reserved. This material may not be reproduced or copied, in whole or in part, in any printed, mechanical, electronic, film, or other distribution and storage media, without the written consent of ASTM International.
You do not currently have access to this content.
